Letrozole Treatment in Normal and GnRH Deficient Women
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This research study involves the use of the drugs Letrozole, GnRH, and NAL-GLU GnRH
antagonist. Letrozole is a drug that is approved by the U.S. Food and Drug Administration
(FDA) for use in breast cancer treatment that has been found to block the formation of
estrogen. The NAL-GLU GnRH antagonist is a drug that temporarily blocks the action of GnRH.
GnRH is a hormone that the body makes that stimulates other hormones that then control the
function of the ovary.
The purpose is to study the effects of the administration of letrozole in women with GnRH
deficiency at the same time that they receive gonadotropin-releasing hormone (GnRH). In
addition, administration of letrozole and NAL-GLU GnRH antagonist in healthy women with
normal menstrual cycles will be done to evaluate the role of estrogen in the control of the
hormone FSH, or Follicle Stimulating Hormone, in the female reproductive cycle. A better
understanding of FSH control may help in the development of new treatments for women with
difficulty conceiving.